Immuno-PET data demonstrated that this radioimmunoconjugate can be used for noninvasive imaging of CD138 expression in MM and has high tumor-to-background tissue contrast, superior to 18F-FDG-PET. This evidence concerns the gene SDC1 and neoplasm.